Bengt Robertson

This inventor holds 7 USPTO granted patents, plus 4 CIPO patents and 3 EPO patents. Top assignee: Chiesi Farmaceutici S.p.a.. Active years: 2009-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bengt Robertson. Retrieved from https://idiyas.com/inventor/bengt-robertson

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 100.0

CIPO Patents = 4

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 3.8

ph-index = 2

Forward Citations = 21(Granted Patents)

Location History:

Stockholm, SE (2012)
Parma, IT (2009 - 2016)

Company Filing History:

7 out of 342

Chiesi Farmaceutici S.p.a.

patents

Years Active: 2009-2016

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9238058 - Reconstituted surfactants having improved properties (2016-01-19),

2. 8183210 - Reconstituted surfactants having improved properties (2012-05-22),

3. 8148492 - Synthetic pulmonary surfactant peptides (2012-04-03),

4. 7897577 - Reconstituted surfactants having improved properties (2011-03-01),

5. 7842664 - Synthetic lipid mixtures for the preparation of a reconstituted surfactant (2010-11-30),

6. 7811988 - Lipid mixtures for synthetic surfactants (2010-10-12),

7. 7511011 - Synthetic lipid mixtures for the preparation of a reconstituted surfactant (2009-03-31),

Title: Innovations by Bengt Robertson

Introduction

Bengt Robertson is a notable inventor based in Parma, Italy. He has made significant contributions to the field of respiratory medicine, holding a total of 7 patents. His work focuses on developing advanced surfactants that can improve treatment outcomes for respiratory disorders.

Latest Patents

Robertson's latest patents include innovative formulations of reconstituted surfactants. These surfactants comprise a lipid carrier, a polypeptide analog of the native surfactant protein SP-C, and a polypeptide analog of the native surfactant protein SP-B. They are designed to be useful for the treatment and/or prophylaxis of respiratory distress syndrome (RDS) and other respiratory disorders.

Career Highlights

Bengt Robertson has established a successful career in pharmaceutical innovation. He is currently associated with Chiesi Farmaceutici S.p.a., where he continues to develop groundbreaking solutions for respiratory health. His expertise and dedication have positioned him as a key figure in his field.

Collaborations

Robertson collaborates with esteemed professionals, including his coworker Tore Curstedt. Their combined efforts contribute to the advancement of respiratory therapies and innovations.

Conclusion

Bengt Robertson's work exemplifies the impact of innovation in medicine, particularly in the treatment of respiratory conditions. His patents and collaborations highlight his commitment to improving patient outcomes through scientific advancements.

Profile summary based on public USPTO records.